Tuomas T. Rissanen

European Society of Cardiology: Cardiovascular Disease Statistics 2019

Adam Timmis, Nick Townsend, Chris P Gale et al. · European Heart Journal · 2019 · 1K citations · Full text

Public Health, Cardiology, Chronic Disease Prevention +16

VEGF-D Is the Strongest Angiogenic and Lymphangiogenic Effector Among VEGFs Delivered Into Skeletal Muscle via Adenoviruses

Tuomas T. Rissanen, Johanna E. Markkanen, Marcin Gruchała et al. · Circulation Research · 2003 · 445 citations

Medicine, Bioengineering, Molecular Medicine +17

VEGF-B is dispensable for blood vessel growth but critical for their survival, and VEGF-B targeting inhibits pathological angiogenesis

Fan Zhang, Zhongshu Tang, Xu Hou et al. · Proceedings of the National Academy of Sciences · 2009 · 308 citations · Full text

Medicine, Molecular Medicine, Pharmacology +14

Drug-coated balloon for treatment of de-novo coronary artery lesions in patients with high bleeding risk (DEBUT): a single-blind, randomised, non-inferiority trial

Tuomas T. Rissanen, Sanna Uskela, Jaakko Eränen et al. · The Lancet · 2019 · 242 citations

Medicine, Cardiology, Pharmacotherapy +13

Vascular Endothelial Growth Factor-B Induces Myocardium-Specific Angiogenesis and Arteriogenesis via Vascular Endothelial Growth Factor Receptor-1– and Neuropilin Receptor-1–Dependent Mechanisms

Johanna Lähteenvuo, Markku Lähteenvuo, Antti Kivelä et al. · Circulation · 2009 · 195 citations

Medicine, Cardiology, Pharmacology +14